Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 379Lung Neoplasms 246Small Cell Lung Carcinoma 67Colorectal Neoplasms 64Breast Neoplasms 51Ovarian Neoplasms 44Melanoma 44Pancreatic Neoplasms 42Neoplasms 39Neoplasm Metastasis 35Squamous Cell Carcinoma of Head and Neck 33Stomach Neoplasms 27Prostatic Neoplasms 27Head and Neck Neoplasms 26Esophageal Neoplasms 24Endometrial Neoplasms 23Carcinoma, Renal Cell 23Colonic Neoplasms 22Urinary Bladder Neoplasms 20Triple Negative Breast Neoplasms 20Uterine Cervical Neoplasms 19Carcinoma, Hepatocellular 19Sarcoma 13Mesothelioma, Malignant 13Mesothelioma 13Liver Neoplasms 13Rectal Neoplasms 12Parkinson Disease 4, Autosomal Dominant Lewy Body 12Lung Diseases 12Thyroid Neoplasms 11

Interventions

patritumab deruxtecan 1durvalumab 1Pemetrexed 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Non-Small Cell Lung Cancer Metastatic × Thoracic × 30 days × Clear all
NCT04163432 2026-05-19

STAGGER

University of Utah

Phase 2 Active not recruiting
43 enrolled 12 charts
Thoracic

Non-Small Cell Lung Cancer Metastatic

NCT04619004 2026-05-14

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Daiichi Sankyo

Phase 2 Active not recruiting
277 enrolled 16 charts
Thoracic

Non-Small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡